Summary
In a significant market movement during November 2021, bit.bio was the subject of a vc funding. The transaction achieved a gross valuation of £76,036,221. Leading the round was Resilience, Metaplanet, Charles River Laboratories, Puhua Capital, Arch Ventures, Tencent, Foresite Capital.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Resilience
Lead Investor / Acquirer
Metaplanet
Lead Investor / Acquirer
Charles River Laboratories
Lead Investor / Acquirer
Puhua Capital
Lead Investor / Acquirer
Arch Ventures
Lead Investor / Acquirer
Tencent
Lead Investor / Acquirer
Foresite Capital
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series B prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in